{Reference Type}: Journal Article
{Title}: Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life.
{Author}: Muzellec L;Bourien H;Edeline J;Muzellec L;Bourien H;Edeline J;
{Journal}: Cancers (Basel)
{Volume}: 14
{Issue}: 1
{Year}: Dec 2021 30
{Factor}: 6.575
{DOI}: 10.3390/cancers14010179
{Abstract}: Quality of life (QoL) in oncology is an outcome becoming more and more important and relevant to explore. Some studies have demonstrated its prognostic impact in different cancers, such as colorectal, breast, and prostate cancers, but also in hepatocellular carcinoma (HCC). Different tools have been developed for assessing quality of life, some general, such as EORTC QLQ-C30, but also specific tools depending on cancer origin which seem to be more pertinent for patients. Systemic treatments and specific symptoms due to cancer evolution could decrease quality of life. For approval of new systemic treatments, authorities ask for benefit in terms of efficacy but also benefit in quality of life, which is crucial for patients. This review reports data about QoL in HCC, including specific tools used, impact of systemic treatments and prognosis for QoL for HCC patients. Management of adverse events is essential to enhance compliance with treatment and quality of life. Assessing quality of life in clinical trials appears quite systematic, but its application in clinical routine requires development.